Idexx LaboratoriesIDXX
IDXX
About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Employees: 11,000
0
Funds holding %
of 6,812 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
4% more first-time investments, than exits
New positions opened: 103 | Existing positions closed: 99
0% more funds holding
Funds holding: 1,090 [Q2] → 1,094 (+4) [Q3]
2% less capital invested
Capital invested by funds: $37.4B [Q2] → $36.5B (-$834M) [Q3]
4.21% less ownership
Funds ownership: 92.88% [Q2] → 88.67% (-4.21%) [Q3]
14% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 12 (-2) [Q3]
17% less repeat investments, than reductions
Existing positions increased: 351 | Existing positions reduced: 425
46% less call options, than puts
Call options by funds: $95M | Put options by funds: $176M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$435
6%
upside
Avg. target
$498
21%
upside
High target
$575
40%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Leerink Partners Daniel Clark 0% 1-year accuracy 0 / 2 met price target | 22%upside $500 | Outperform Initiated | 2 Dec 2024 |
Piper Sandler David Westenberg 69% 1-year accuracy 27 / 39 met price target | 6%upside $435 | Neutral Reiterated | 4 Nov 2024 |
Barclays Balaji Prasad 48% 1-year accuracy 21 / 44 met price target | 17%upside $481 | Overweight Maintained | 4 Nov 2024 |
JP Morgan Chris Schott 29% 1-year accuracy 5 / 17 met price target | 40%upside $575 | Overweight Maintained | 11 Oct 2024 |
Stifel Jonathan Block 6% 1-year accuracy 1 / 18 met price target | 22%upside $500 | Hold Maintained | 10 Oct 2024 |
Financial journalist opinion
Based on 5 articles about IDXX published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
GlobeNewsWire
1 week ago
SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX
Sustainability Roundtable Inc. announced Synopsys, IDEXX, and Juniper Networks as winners of the 2024 SBER Awards for standout leadership in sustainability
Positive
The Motley Fool
2 weeks ago
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025
One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities.
Positive
Zacks Investment Research
2 weeks ago
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues
IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth.
Neutral
Business Wire
3 weeks ago
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company's common stock. Repurchases may be made at management's discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. Thes.
Positive
Zacks Investment Research
1 month ago
Should You Hold IDEXX Stock in Your Portfolio for Now?
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Neutral
Business Wire
1 month ago
IDEXX Announces CFO Transition
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX's Executive Vice President, Chief Financial Officer and Treasurer, effective March 1, 2025. Mr. McKeon will serve as EVP and Special Advisor to the Co.
Neutral
Business Wire
1 month ago
ACVIM and IDEXX Partner to Provide Free Educational Offerings for ACVIM Residents
DENVER--(BUSINESS WIRE)--The American College of Veterinary Internal Medicine (ACVIM) is excited to announce a new endorsement partnership with IDEXX Laboratories, Inc., of complimentary resident-focused educational resources through their SpringBoard program. This partnership ensures access to high-quality content, evaluated and endorsed by ACVIM, that meets the standards of scientific accuracy and professional relevance for our specialists in training. The demand for reliable online education.
Negative
Seeking Alpha
1 month ago
IDEXX Laboratories Q3: Weak End-Market Demand Continues
I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth.
Neutral
The Motley Fool
1 month ago
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
Charts implemented using Lightweight Charts™